Overview

The ATTAIN Study: A Therapeutic Trial of Afatinib In the Neoadjuvant Setting

Status:
Terminated
Trial end date:
2017-08-16
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if it is tolerable for patients with NSCLC to receive afatinib before surgery. The safety of this drug will also be studied.
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
Boehringer Ingelheim
Treatments:
Afatinib